A
latest report released by Data Bridge Market Research on Global Bulbospinal
Muscular Atrophy Drugs Market covering key business segments and wide scope
geographies to get deep dive analysed market data. The study is a perfect
balance bridging both qualitative and quantitative information of Bulbospinal
Muscular Atrophy Drugs Market.
The
study provides historical data (i.e. Size, Share, Volume & Value) from 2017
to 2018 and forecasted till 2026. Some are the key & emerging players that
are part of coverage and have being profiled are Novartis AG, F. Hoffmann-La
Roche Ltd, Boehringer Ingelheim International GmbH, Pfizer Inc, Ionis
Pharmaceuticals, Inc, CYTOKINETICS, INC., Others.
Global
Bulbospinal Muscular Atrophy Drugs Market is growing at a steady CAGR in the
forecast period of 2019-2026. The report contains data of the base year 2018
and historic year 2017. This rise
in market value can be attributed to the granting of various drug designations
to novel drugs by the U.S FDA, initiatives undertaken by various public, as
well as nonprofit, organizations for creating awareness regarding bulbospinal
muscular atrophy and increase in R&D investment by major companies.
Request
For Sample Report @ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-bulbospinal-muscular-atrophy-drugs-market
Market
Definition:
Bulbospinal
muscular atrophy is also known as Kennedy’s disease, a rare adult-onset form of
spinal muscular atrophy (SMA) is an X-linked autosomal recessive progressive
neurodegenerative disorder that causes weakening and wasting of the proximal
and bulbar muscles. The condition occurs due to loss of nerve cells in the
brain stem and spinal cord, this result in stoppage of messages from brain to
muscles for movement. Patients with bulbospinal muscular atrophy have
difficulty in speaking, standing, walking and controlling their head movements.
In worse condition patients can have trouble swallowing and breathing. This
disorder mainly affects men and does not occur in females, who are protected by
their low levels of testosterone in the body, accounting for the sex-limited
inheritance pattern of this disorder.
According
to National Organization for Rare Disorders, Bulbospinal muscular atrophy or
Kennedy disease is a very rare type of disorder and it affects 1 in 350,000
males and rarely seen in females. The Japanese population has a very high
prevalence of this disorder because of a founder effect.
Market
Drivers
- Growing number of incidences of
spinal bulbar muscular atrophy is driving the growth of the market
- Initiatives undertaken by
various public, as well as nonprofit, organizations for creating awareness
regarding bulbospinal muscular atrophy also acts as a market driver
- Increase in R&D investment
by major companies is boosting the market growth
- Increasing healthcare
expenditure can also enhance the market growth
Market
Restraints
- High cost of treatment for
bulbospinal muscular atrophy is hindering the market growth
- Lack of experienced
professionals in this field can also act as a restricting factor for the
growth of this market
- Limited number of drugs available
for bulbospinal muscular atrophy treatment also hampers the market growth
Segmentation:
By
Drugs Class
- 5α-Reductase Inhibitors
(5-ARIs)
- Gonadotropin-releasing Hormone
(GnRH) Agonists
- Others
By
Drugs
- Leuprorelin
- Dutasteride
- Others
By
Therapy
- Physical Therapy
- Occupational Therapy
- Speech Therapy
By Treatment
- Medication
- Supportive Care
- Surgery
By Route
of Administration
- Oral
- Parenteral
By
Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
By
End-Users
- Hospitals
- Homecare
- Specialty Clinics
By
Geography
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- Italy
- U.K.
- France
- Spain
- Netherlands
- Belgium
- Switzerland
- Turkey
- Russia
- Rest of Europe
- Asia-Pacific
- Japan
- China
- India
- South Korea
- Australia
- Singapore
- Malaysia
- Thailand
- Indonesia
- Philippines
- Rest of Asia Pacific
- South America
- Brazil
- Rest of South America
- Middle East & Africa
- South Africa
- Rest of Middle East &
Africa
For
More Details In-Depth Inquiry @ https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-bulbospinal-muscular-atrophy-drugs-market
Key
Developments in the Market
- In April 2019, Novartis AG is
developing BVS857, a novel drug for the treatment of bulbospinal muscular
atrophy, currently ongoing in phase ll clinical trial. If approved this
novel drug will provide a potential treatment for patients with
bulbospinal muscular atrophy and help in improving their life
- In August 2018, Takeda
Pharmaceutical Company Limited is developing Leuprorelin, a
gonadotropin-releasing hormone (GnRH) agonist for the treatment of
bulbospinal muscular atrophy. If approved this drug will provide a
potential treatment for patients with bulbospinal muscular atrophy
Competitive
Analysis:
Global
bulbospinal muscular atrophy drugs market is highly fragmented and the major
players have used various strategies such as new product launches, expansions,
agreements, joint ventures, partnerships, acquisitions, and others to increase
their footprints in this market. The report includes market shares of
bulbospinal muscular atrophy drugs market for Global, Europe, North America, Asia-Pacific,
South America and Middle East & Africa.
Reasons
to Purchase this Report:
- Current and future of global
bulbospinal muscular atrophy drugs market outlook in the developed and
emerging markets.
- The segment that is expected to
dominate the market as well as the segment which holds highest CAGR in the
forecast period.
- Regions/Countries that are
expected to witness the fastest growth rates during the forecast period.
- The latest developments, market
shares, and strategies that are employed by the major market players.
Table
of Contents:
- Introduction
- Market Segmentation
- Market Overview
- Executive Summary
- Premium Insights
- Global, By Component
- Product Type
- Delivery
- Industry Type
- Geography
10.1.
Overview
10.2.
North America
10.3.
Europe
10.4.
Asia-Pacific
10.5.
South America
10.6.
Middle East & Africa
- Company Landscape
- Company Profiles
- Related Reports
Access
Detailed TOC @ https://www.databridgemarketresearch.com/toc/?dbmr=global-bulbospinal-muscular-atrophy-drugs-market
About
Data Bridge Market Research
An
absolute way to forecast what future holds is to comprehend the trend today!
Data
Bridge set forth itself as an unconventional and neoteric Market research and
consulting firm with unparalleled level of resilience and integrated
approaches. We are determined to unearth the best market opportunities and
foster efficient information for your business to thrive in the market. Data
Bridge endeavors to provide appropriate solutions to the complex business
challenges and initiates an effortless decision-making process. Data Bridge is
an aftermath of sheer wisdom and experience which was formulated and framed in
the year 2015 in Pune.
Contact:
Data
Bridge Market Research
US:
+1 888 387 2818
UK:
+44 208 089 1725
Hong
Kong: +852 8192 7475